{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:05Z","timestamp":1791644765280,"version":"4.3.4"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To compare the efficacy of 0.15% hyaluronic acid (HA), 0.05% cyclosporine A (CsA) and 3% diquafosol sodium (DQS) ophthalmic solution for the treatment of moderate-to-severe dry eye disease (DED) in college students and the effect on inflammatory factors in tears.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a prospective, randomized, multicenter trial. A total of 282 college students diagnosed with moderate-to-severe DED between October 2, 2022 and March 1, 2023 were included. A total of 282 patients were randomized to treatment in the group of 0.15% HA or 0.05% CsA or 3% DQS in a 1:1:1 assignment. There was a main end point which is the variations in the corneal staining score to determine non-inferiority of 0.15% HA. Secondary target end points were ocular surface disease index score, Schirmer test, tear meniscus height and tear film breakup time. In addition, the inflammatory factor levels of Interleukin-1\u03b2, Interleukin-6, transforming growth factor-\u03b21 in tears were measured. Effectiveness was assessed at baseline, 4- and 12-weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In our analysis, the average change from baseline in corneal staining score confirmed non-inferiority of 0.15% HA to 0.05% CsA and 3% DQS and manifested obvious improvement of all groups as well (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). Values for ocular surface disease index score, Schirmer test, tear meniscus height and tear film breakup time showed obvious improvements in all groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05), however, the difference intergroup was not statistically significant. Value for inflammatory factor was significant improvement across all groups, although inflammatory factor scores in the 0.05% CsA group showed a clear trend of better improvement at 12 weeks compared with 0.15% HA groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .01). No serious adverse reactions were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>College students taking 0.15% HA had clinically and statistically significant improvement in corneal staining score and other indicators, but it was inferior to 0.05% CsA in anti-inflammatory therapy for moderate to severe DED. However, 0.15% HA is still an effective, safe and well-tolerated treatment option that may offer additional benefits in terms of convenience and compliance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034923","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:01:35Z","timestamp":1694181695000},"page":"e34923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5248-6747","authenticated-orcid":false,"given":"Wenhao","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of Yanbian University, Yanji, China"},{"name":"Yanbian University, Yanji, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of Yanbian University, Yanji, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of Yanbian University, Yanji, China"},{"name":"Department of Ophthalmology, Fuzhi Hospital of Yanbian University, Yanji, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of Yanbian University, Yanji, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fali","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of Yanbian University, Yanji, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of Yanbian University, Yanji, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengri","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of Yanbian University, Yanji, China"},{"name":"Yanbian University, Yanji, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/ijms24021458","article-title":"Dry eye disease: what is the role of Vitamin D?","volume":"24","author":"Rolando","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R2-20250504","first-page":"593","article-title":"Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction.","volume":"11","author":"Kim","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3109\/02713683.2014.969810","article-title":"Combining sodium hyaluronate and polyvinylpyrrolidone therapies for the rabbit cornea: a new approach to relief of the human dry eye syndrome.","volume":"40","author":"Ehrenberg","year":"2015","journal-title":"Curr Eye Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jamaophthalmol.2022.0140","article-title":"Association between depression and severity of dry eye symptoms, signs, and inflammatory markers in the DREAM study.","volume":"140","author":"Zhou","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"9256482","DOI":"10.1155\/2018\/9256482","article-title":"Novel mechanisms modulating palmitate-induced inflammatory factors in hypertrophied 3T3-L1 adipocytes by AMPK.","volume":"2018","author":"Morita","year":"2018","journal-title":"J Diabetes Res"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/OED.S16067","article-title":"Safety and efficacy of cyclosporine in the treatment of chronic dry eye.","volume":"6","author":"Schultz","year":"2014","journal-title":"Ophthalmol Eye Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1076\/ceyr.21.4.782.5550","article-title":"P2Y(2) receptor stimulation increases tear fluid secretion in rabbits.","volume":"21","author":"Murakami","year":"2000","journal-title":"Curr Eye Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/10807680260218524","article-title":"INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model.","volume":"18","author":"Fujihara","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/ICO.0b013e3182930b1d","article-title":"Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye.","volume":"32","author":"Shimazaki-Den","year":"2013","journal-title":"Cornea"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jtos.2014.12.001","article-title":"Clinical guidelines for management of dry eye associated with Sj\u00f6gren disease.","volume":"13","author":"Foulks","year":"2015","journal-title":"Ocul Surf"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group [published correction appears in Ophthalmology 2000 Jul;107(7):1220].","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","article-title":"Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.","volume":"119","author":"Matsumoto","year":"2012","journal-title":"Ophthalmology"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10916-018-1086-3","article-title":"An automated grading and diagnosis system for evaluation of dry eye syndrome.","volume":"42","author":"Ba\u011fbaba","year":"2018","journal-title":"J Med Syst"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index.","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jtos.2020.07.019","article-title":"Dry eye disease in children and adolescents in India.","volume":"18","author":"Donthineni","year":"2020","journal-title":"Ocul Surf"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12325-012-0033-9","article-title":"Diquafosol ophthalmic solution for dry eye treatment.","volume":"29","author":"Nakamura","year":"2012","journal-title":"Adv Ther"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","article-title":"A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients.","volume":"96","author":"Takamura","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/DDDT.S370559","article-title":"Cyclosporine A (0.05%) ophthalmic gel in the treatment of dry eye disease: a multicenter, randomized, double-masked, phase III, COSMO trial.","volume":"16","author":"Peng","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e0224805","DOI":"10.1371\/journal.pone.0224805","article-title":"Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.","volume":"14","author":"Bang","year":"2019","journal-title":"PLoS One"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jama.2021.19963","article-title":"Dry eye disease: an update in 2022.","volume":"327","author":"Hakim","year":"2022","journal-title":"JAMA"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1177\/11206721221088259","article-title":"Dry eye disease, a prominent manifestation of systemic autoimmune disorders.","volume":"32","author":"Bustamante-Arias","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments.","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/OPTH.S1409","article-title":"Treatment of chronic dry eye: focus on cyclosporine.","volume":"2","author":"Kymionis","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"R26-20250504","first-page":"CD013520","article-title":"Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.","volume":"3","author":"Liu","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1477-7525-2-44","article-title":"Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sj\u00f6gren\u2019s syndrome-related dry eye.","volume":"2","author":"Vitale","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"R29-20250504","first-page":"1484","article-title":"Comparing Tear Film Viscosity between Sj\u00f6gren and Non-Sj\u00f6gren Dry Eye Disease.","volume":"13","author":"Lai","year":"2023","journal-title":"Life (Basel)"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"e16995","DOI":"10.1016\/j.heliyon.2023.e16995","article-title":"International survey on dry eye diagnosis by experts.","volume":"9","author":"Cartes","year":"2023","journal-title":"Heliyon"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4274\/tjo.galenos.2022.58153","article-title":"Conjunctival Impression Cytology and Tear Film Changes in Sarcoidosis: A Subjective and Objective Diagnosis Study.","volume":"53","author":"Ero\u011ful","year":"2023","journal-title":"Turk J Ophthalmol"},{"key":"R32-20250504","article-title":"Diagnosing dry-eye: Which tests are most accurate?","volume":"102048","author":"Papas","year":"2023","journal-title":"Cont Lens Anterior Eye"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.optm.2010.08.003","article-title":"A review of hyaluronan and its ophthalmic applications.","volume":"82","author":"Rah","year":"2011","journal-title":"Optometry"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/bjo.2003.027573","article-title":"Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro.","volume":"88","author":"Gomes","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"Pt 4","key":"R35-20250504","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/eye.1990.83","article-title":"Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy.","volume":"4 (Pt 4)","author":"Snibson","year":"1990","journal-title":"Eye (Lond)"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bjo.86.2.181","article-title":"Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye.","volume":"86","author":"Aragona","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/elps.201200342","article-title":"Hyaluronic acid-dependent protection against alkali-burned human corneal cells.","volume":"34","author":"Wu","year":"2013","journal-title":"Electrophoresis"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","article-title":"Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine [published correction appears in Arch Ophthalmol 2002 Aug;120(8):1099].","volume":"120","author":"Kunert","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2019.0060","article-title":"The immunological basis of dry eye disease and current topical treatment options.","volume":"36","author":"Periman","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","article-title":"A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore.","volume":"99","author":"Gong","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"9091","DOI":"10.1038\/s41598-019-45475-7","article-title":"Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study.","volume":"9","author":"Fukuoka","year":"2019","journal-title":"Sci Rep"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/ICO.0000000000000213","article-title":"Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.","volume":"33","author":"Hwang","year":"2014","journal-title":"Cornea"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/OPTH.S184412","article-title":"Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease.","volume":"13","author":"de Oliveira","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1442-9071.2009.02134.x","article-title":"Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery.","volume":"37","author":"Fakhraie","year":"2009","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:29:00Z","timestamp":1746325740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":44,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034923","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}